NanoViricides surged 7.1% to $1.37 today after providing a positive update on its NV-387 Phase IIA Ebola trial. - The company announced on October 5, 2026, that the trial is proceeding as designed, with enrollment for Phase IIA having begun around September 23, 2026. - Phase IIA is focused on evaluating tolerability and dosing, with a randomized Phase IIB intended to assess efficacy. - This update served as a significant company-specific catalyst for the stock's gain.